Oxaprotiline | CAS#56433-44-4 |

MedKoo Cat#: 592562 | Name: Oxaprotiline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxaprotiline is an Antidepressive Agent.

Chemical Structure

Oxaprotiline

CAS#56433-44-4

Theoretical Analysis

MedKoo Cat#: 592562

Name: Oxaprotiline

CAS#: 56433-44-4

Chemical Formula: C20H23NO

Exact Mass: 293.1780

Molecular Weight: 293.41

Elemental Analysis: C, 81.87; H, 7.90; N, 4.77; O, 5.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Oxaprotilinum; Oxaprotiline

IUPAC/Chemical Name

09,10-Ethanoanthracene-9(10H)-ethanol, alpha-((methylamino)methyl)-

InChi Key

FDXQKWSTUZCCTM-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H23NO/c1-21-13-14(22)12-20-11-10-15(16-6-2-4-8-18(16)20)17-7-3-5-9-19(17)20/h2-9,14-15,21-22H,10-13H2,1H3

SMILES Code

OC(CNC)CC12C3=C(C=CC=C3)C(CC2)C4=CC=CC=C14

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 293.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Birthelmer A, Ehret A, Riegert C, Rothmaier AK, Leemhuis J, Jackisch R. Modulation of electrically evoked serotonin release in cultured rat raphe neurons. J Neurochem. 2007 Mar;100(6):1613-25. PubMed PMID: 17348865. 2: Ding YS, Lin KS, Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des. 2006;12(30):3831-45. Review. PubMed PMID: 17073682. 3: Löffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R, Feuerstein TJ. Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain Res Bull. 2006 Jan 30;68(5):361-73. Epub 2005 Oct 17. PubMed PMID: 16377444. 4: Ding YS, Lin KS, Logan J, Benveniste H, Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem. 2005 Jul;94(2):337-51. PubMed PMID: 15998285. 5: Lin KS, Ding YS. Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons. Bioorg Med Chem. 2005 Aug 1;13(15):4658-66. PubMed PMID: 15914010. 6: Eckhardt K, Roth P, Günter T, Schmidt S, Feuerstein TJ. Differential effects of K(ATP) channel blockers on [(3)H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):168-75. Epub 2003 Jan 18. PubMed PMID: 12595958. 7: Scheibner J, Trendelenburg AU, Hein L, Starke K. Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice. Br J Pharmacol. 2001 Feb;132(4):925-33. PubMed PMID: 11181434; PubMed Central PMCID: PMC1572622. 8: Taylor D, Walden JC, Robins AH, Smith PJ. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in Plasmodium falciparum. Antimicrob Agents Chemother. 2000 Oct;44(10):2689-92. PubMed PMID: 10991845; PubMed Central PMCID: PMC90136. 9: Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr Scand Suppl. 2000;402:28-36. Review. PubMed PMID: 10901156. 10: Wesołowska A, Borycz J. Participation of opioid mechanism in the antinociceptive effects induced by oxaprotiline enantiomers in mice. Pol J Pharmacol. 1999 Jul-Aug;51(4):367-71. PubMed PMID: 10540970. 11: Gray AM, Pache DM, Sewell RD. Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol. 1999 Aug 6;378(2):161-8. PubMed PMID: 10478628. 12: Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol. 1998 Jun;124(4):669-74. PubMed PMID: 9690858; PubMed Central PMCID: PMC1565439. 13: Nörenberg W, Schöffel E, Szabo B, Starke K. Subtype determination of soma-dendritic alpha2-autoreceptors in slices of rat locus coeruleus. Naunyn Schmiedebergs Arch Pharmacol. 1997 Aug;356(2):159-65. PubMed PMID: 9272720. 14: Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry. 1997;12(4):166-76. doi: 10.1016/S0924-9338(97)89100-6. PubMed PMID: 19698527. 15: Eiring A, Sulser F. Increased synaptic availability of norepinephrine following desipramine is not essential for increases in GR mRNA. Short communication. J Neural Transm (Vienna). 1997;104(11-12):1255-8. PubMed PMID: 9503270. 16: Dziedzicka-Wasylewska M, Rogoz R, Klimek V, Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J Neural Transm (Vienna). 1997;104(4-5):515-24. PubMed PMID: 9295182. 17: Rogoz R, Dziedzicka-Wasylewska M. Comparison of the effects of antidepressant drugs on the level of cAMP in the rat striatum and nucleus accumbens septi. Pol J Pharmacol. 1996 Sep-Oct;48(5):481-7. PubMed PMID: 9112689. 18: Parker G. Recovery from depression: triggers and time patterns. Aust N Z J Psychiatry. 1996 Aug;30(4):442-4. PubMed PMID: 8887691. 19: Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry. 1996 May;29(3):87-96. PubMed PMID: 8738312. 20: Paczkowski NJ, Vuocolo HE, Bryan-Lluka LJ. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):423-30. PubMed PMID: 8935709.